open access

Vol 63, No 2 (2012)
Original papers
Published online: 2012-04-27
Submitted: 2013-02-15
Get Citation

Serum interleukin-16 and RANTES during treatment of Graves′ orbitopathy with corticosteroids and teleradiotherapy

Janusz Mysliwiec, Iwona Palyga, Agnieszka Nikolajuk, Aldona Kowalska, Maria Gorska
Endokrynologia Polska 2012;63(2):92-96.

open access

Vol 63, No 2 (2012)
Original papers
Published online: 2012-04-27
Submitted: 2013-02-15

Abstract

Introduction: To assess the usefulness of circulating IL-16 and RANTES measurements as markers of Graves′ orbitopathy (GO) activity and to estimate the role of these cytokines in GO pathogenesis.
Material and methods: 42 individuals were divided into four groups: Group 1 comprised 15 euthyroid patients with clinical symptoms of GO who underwent corticosteroid therapy consisting of intravenous infusions of methylprednisolone (MP) and teleradiotherapy (TR); Group 2 comprised ten patients with hyperthyroid GD (Gtx); Group 3 comprised ten patients with GD in euthyreosis (Geu); and Group 4 comprised seven healthy volunteers age- and sex-matched to Groups 1–3. Serum samples were collected 24 hours before the first dose of MP, 24 hours after the first dose of MP, before TR, and at the end of therapy. Serum IL-16 and RANTES were determined by ELISA and TSH-Rab by RIA.
Results: Serum IL-16 levels in patients with GO were significantly elevated at the end of therapy: 346 pg/mL (257–538) compared to IL-16 values before treatment: 250 ng/mL (211–337) and to the control group. RANTES serum concentrations did not significantly differ between studied groups, and immunosuppressive treatment did not influence its level. A negative correlation between TSH-Rab and RANTES was found in all studied groups (R = –0.32, p < 0.01). Conclusions: Our data suggests that IL-16 may exert an immunoregulatory effect in Graves′ orbitopathy. Serum measurements of both IL-16 and RANTES may be clinically useful; however, establishing their place in the diagnostics and treatment monitoring of GO needs further research. (Pol J Endocrinol 2012; 63 (2): 92–96)

Abstract

Introduction: To assess the usefulness of circulating IL-16 and RANTES measurements as markers of Graves′ orbitopathy (GO) activity and to estimate the role of these cytokines in GO pathogenesis.
Material and methods: 42 individuals were divided into four groups: Group 1 comprised 15 euthyroid patients with clinical symptoms of GO who underwent corticosteroid therapy consisting of intravenous infusions of methylprednisolone (MP) and teleradiotherapy (TR); Group 2 comprised ten patients with hyperthyroid GD (Gtx); Group 3 comprised ten patients with GD in euthyreosis (Geu); and Group 4 comprised seven healthy volunteers age- and sex-matched to Groups 1–3. Serum samples were collected 24 hours before the first dose of MP, 24 hours after the first dose of MP, before TR, and at the end of therapy. Serum IL-16 and RANTES were determined by ELISA and TSH-Rab by RIA.
Results: Serum IL-16 levels in patients with GO were significantly elevated at the end of therapy: 346 pg/mL (257–538) compared to IL-16 values before treatment: 250 ng/mL (211–337) and to the control group. RANTES serum concentrations did not significantly differ between studied groups, and immunosuppressive treatment did not influence its level. A negative correlation between TSH-Rab and RANTES was found in all studied groups (R = –0.32, p < 0.01). Conclusions: Our data suggests that IL-16 may exert an immunoregulatory effect in Graves′ orbitopathy. Serum measurements of both IL-16 and RANTES may be clinically useful; however, establishing their place in the diagnostics and treatment monitoring of GO needs further research. (Pol J Endocrinol 2012; 63 (2): 92–96)
Get Citation

Keywords

cytokines; chemokines; TSH-Rab; Graves’ disease; orbitopathy

About this article
Title

Serum interleukin-16 and RANTES during treatment of Graves′ orbitopathy with corticosteroids and teleradiotherapy

Journal

Endokrynologia Polska

Issue

Vol 63, No 2 (2012)

Pages

92-96

Published online

2012-04-27

Bibliographic record

Endokrynologia Polska 2012;63(2):92-96.

Keywords

cytokines
chemokines
TSH-Rab
Graves’ disease
orbitopathy

Authors

Janusz Mysliwiec
Iwona Palyga
Agnieszka Nikolajuk
Aldona Kowalska
Maria Gorska

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl